The Worldwide Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies

Overview

Journal Can J Urol

Specialty Urology

Date 2008 Feb 29

PMID 18304396

Citations 161

Authors

Gabriel P Haas

Nicolas Delongchamps

Otis W Brawley

Ching Y Wang

Gustavo de la Roza

Affiliations

Soon will be listed here.

Abstract

Introduction: Prostate cancer is the most frequently diagnosed non-skin cancer in the United States and the third leading cause of cancer deaths. International trends in the incidence, mortality and prevalence of prostate cancer are assessed.

Methods: Databases from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute and the International Agency for Research on Cancer (IARC), and the literature on autopsy studies on prostate cancer were reviewed and summarized in the article.

Results: Prostate cancer remains an important public health concern in Western countries and an emerging malignancy in developing nations. Prostate cancer incidence is dependent on efforts to detect the disease. Autopsy studies provide accurate and useful information regarding comparative prevalence rates of the disease among regions of interest.

Conclusions: Improved cancer registration is needed in developing nations. The prevalence of prostate cancer must be established to predict the expected incidence of the disease and in order to plan rational detection and treatment strategies. Clinically significant disease should be distinguished from insignificant disease which may pose little or no biological danger to the patient.

Citing Articles

More micrometastases, more recurrence? The role of qPCR of PSA mRNA in lymph nodes during prostatectomy.

Troidl J, Fehr A, Jandrig B, Kollermann J, Lux A, Baumunk D World J Urol. 2025; 43(1):62.

PMID: 39755981 PMC: 11700908. DOI: 10.1007/s00345-024-05414-2.

Global burden of cancer and associated risk factors in 204 countries and territories, 1980-2021: a systematic analysis for the GBD 2021.

Wu Z, Xia F, Lin R J Hematol Oncol. 2024; 17(1):119.

PMID: 39614359 PMC: 11607901. DOI: 10.1186/s13045-024-01640-8.

Effective Use of DCM Root Extract Encapsulated by Thermosensitive Immunoliposomes for Targeted Drug Delivery in Prostate Cancer Cells.

Riet K, Adegoke A, Mashele S, Sekhoacha M Curr Issues Mol Biol. 2024; 46(11):12037-12060.

PMID: 39590308 PMC: 11593239. DOI: 10.3390/cimb46110714.

Prostate Cancer Knowledge and Attitude Toward Screening Practices Among Men 40 and Over in the Jazan Region, Saudi Arabia.

Elyas A, Mahfouz M, Suwaydi A, Alotayf O, Tayri A, Daghriri B J Cancer Epidemiol. 2024; 2024:2713372.

PMID: 39544845 PMC: 11561174. DOI: 10.1155/2024/2713372.

To Drink or Not to Drink? Investigating Alcohol's Impact on Prostate Cancer Risk.

Kaltsas A, Chrisofos M, Symeonidis E, Zachariou A, Stavropoulos M, Kratiras Z Cancers (Basel). 2024; 16(20).

PMID: 39456547 PMC: 11506468. DOI: 10.3390/cancers16203453.

References

Haas G, Barry Delongchamps N, Jones R, Chandan V, Serio A, Vickers A . Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007; 99(19):1484-9. DOI: 10.1093/jnci/djm153. View

Cooperberg M, Lubeck D, Meng M, Mehta S, Carroll P . The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22(11):2141-9. PMC: 2997214. DOI: 10.1200/JCO.2004.10.062. View

Yao S, Lu-Yao G . Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst. 2002; 94(13):958-60. DOI: 10.1093/jnci/94.13.958. View

Brawley O, Jani A, Master V . Prostate cancer and race. Curr Probl Cancer. 2007; 31(3):211-25. DOI: 10.1016/j.currproblcancer.2007.01.006. View

Soos G, Tsakiris I, Szanto J, Turzo C, Haas P, Dezso B . The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol. 2005; 48(5):739-44. DOI: 10.1016/j.eururo.2005.08.010. View

Bostwick D, COONER W, Denis L, Jones G, Scardino P, Murphy G . The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992; 70(1 Suppl):291-301. DOI: 10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4. View

Stamatiou K, Alevizos A, Perimeni D, Sofras F, Agapitos E . Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study. Prostate Cancer Prostatic Dis. 2005; 9(1):45-9. DOI: 10.1038/sj.pcan.4500847. View

Singh A, Kinoshita Y, Rovito Jr P, Landas S, Silberstein J, Nsouli I . Higher than expected association of clinical prostate and bladder cancers. J Urol. 2005; 173(5):1526-9. DOI: 10.1097/01.ju.0000154700.80042.c6. View

Epstein J, Walsh P, Carmichael M, Brendler C . Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271(5):368-74. View

10.

Potosky A, Miller B, Albertsen P, Kramer B . The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273(7):548-52. View

11.

Kabalin J, McNeal J, Price H, Freiha F, Stamey T . Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol. 1989; 141(5):1091-4; discussion 1093-4. DOI: 10.1016/s0022-5347(17)41178-5. View

12.

Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J . Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol. 2006; 51(3):659-64. DOI: 10.1016/j.eururo.2006.07.012. View

13.

Montie J, Wood Jr D, Pontes J, Boyett J, Levin H . Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer. 1989; 63(2):381-5. DOI: 10.1002/1097-0142(19890115)63:2<381::aid-cncr2820630230>3.0.co;2-o. View

14.

Etzioni R, Penson D, Legler J, di Tommaso D, Boer R, Gann P . Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002; 94(13):981-90. DOI: 10.1093/jnci/94.13.981. View

15.

Sakr W, Haas G, Cassin B, Pontes J, Crissman J . The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993; 150(2 Pt 1):379-85. DOI: 10.1016/s0022-5347(17)35487-3. View

16.

Kinoshita Y, Singh A, Rovito Jr P, Wang C, Haas G . Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer. 2004; 3(2):83-6. DOI: 10.3816/cgc.2004.n.016. View

17.

Yatani R, Shiraishi T, Nakakuki K, KUSANO I, Takanari H, Hayashi T . Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst. 1988; 80(9):683-7. DOI: 10.1093/jnci/80.9.683. View

18.

Armenian H, LILIENFELD A, Diamond E, Bross I . Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet. 1974; 2(7873):115-7. DOI: 10.1016/s0140-6736(74)91551-7. View

19.

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

20.

Guileyardo J, Johnson W, Welsh R, AKAZAKI K, Correa P . Prevalence of latent prostate carcinoma in two U.S. populations. J Natl Cancer Inst. 1980; 65(2):311-6. View